X

Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care

Holly Campbell   |     September 21, 2017   |   SHARE THIS

Future of Healthcare  Twitter Card4-1.jpgAs part of The Value Collaborative, an initiative of America’s biopharmaceutical companies, we recently hosted an event with Bloomberg about unlocking and supporting value in the future of health care. Breakthrough medicines are revolutionizing how we fight disease, but too often patients have to fight to access these treatments. We can improve access and affordability through market-based reforms such as moving toward a system that prioritizes results for patients.

Joaquin Duato, executive vice president and chairman, pharmaceuticals, Johnson & Johnson and Ian Read,  chairman of the board and CEO, Pfizer participated in the event alongside leadership from Aetna, American Cancer Society, Cleveland Clinic, Duke University, Flatiron Health and Walgreens. PhRMA president and CEO Steve Ubl also participated in a conversation about advancing value-driven health care.

Here is a recap of the event:

  • “5 Questions With…”
    • Moderator:
      • David Gura, anchor, television and radio, Bloomberg
    • Panelists:
      • Steve Ubl, president and CEO, PhRMA
  • Collaborating on High-Value Care and Treatment
    • Moderator:
      • David Gura, anchor, television and radio, Bloomberg
    • Panelists:
      • Delos M. Cosgrove, CEO and president, Cleveland Clinic
      • Stefano Pessina, executive vice chairman and CEO, Walgreens Boots Alliance
      • Ian C. Read, chairman of the board & CEO, Pfizer
      • Gary M. Reedy, CEO, American Cancer Society, Inc.

  • How It Works
    • Moderator:
      • Drew Armstrong, health care reporter, Bloomberg
    • Panelists:
      • Joaquin Duato, executive vice president and chairman, pharmaceuticals, Johnson & Johnson
      • Harold L. Paz, executive vice president and chief medical officer, Aetna

  • Driving Progress
    • Moderator:
      • Anna Edney, health regulation reporter, Bloomberg
    • Panelists:
      • Amy Abernethy, chief medical officer, chief scientific officer & senior vice president, oncology, Flatiron Health
      • Mark McClellan, Robert J. Margolis professor of business, medicine and policy and director, Duke-Margolis Center for Health Policy at Duke University

View past events of The Value Collaborative here.  

Holly Campbell

Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Topics: The Value Collaborative

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates